Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ZyVersa Therapeutics, Inc. - Common Stock (NQ: ZVSA )

1.120 -0.010 (-0.88%)
Streaming Delayed Price Updated: 3:34 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ZyVersa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the... 
Via Benzinga
Why ZyVersa Therapeutics Shares Are Down 40%
ZyVersa Therapeutics Inc (NASDAQ: ZVSA) shares are trading lower by 43.7% to $1.20 Thursday morning. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?
ZyVersa reveals study in Acta Neuropathologica Communications. Learn how inhibiting NLRP3 inflammasome with Inflammasome ASC Inhibitor IC 100 prevents TNBC brain metastasis. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
From ZyVersa Therapeutics
Via GlobeNewswire
This Biotech Is Targeting Indications Worth $70 Billion
Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) was recently a guest on Benzinga’s All-Access. 
Via Benzinga
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket
Shares of Motus GI Holdings, Inc. (NASDAQ: MOTS) shares fell sharply in pre-market trading after the company priced its $5 million public offering. Motus GI Holdings shares dipped 46.5% to $1.15 in... 
Via Benzinga
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
From ZyVersa Therapeutics
Via GlobeNewswire
Dow Surges 100 Points; Ciena Posts Upbeat Earnings
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Thursday. The Dow traded up 0.28% to 36,155 while the NASDAQ rose 1.41% to 14,346.47. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings. 
Via Benzinga
Gold Moves Lower; Dollar General Earnings Beat Estimates
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.06% to 36,077.32 while the NASDAQ rose 1.09% to 14,301.04.... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
From ZyVersa Therapeutics
Via GlobeNewswire
Nasdaq Jumps Over 100 Points; US Jobless Claims Edge Higher
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.04% to 36,068.53 while the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Rivian (RIVN) Stock Just Scored a New ‘Buy’ Rating
Rivian stock is gaining on Thursday after Stifel weighed in on RIVN shares with a buy rating and set a price target of $25 per share. 
Via InvestorPlace
Why Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today?
ZyVersa Therapeutics stock is falling hard on Thursday after the company priced a public offering for shares of ZVSA this morning. 
Via InvestorPlace
Why Cerevel Therapeutics Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) jumped in pre-market trading after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity value of approximately... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! 
Via InvestorPlace
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
From ZyVersa Therapeutics
Via GlobeNewswire
Shopify (SHOP) Stock Falls Following Analyst Downgrade
Shopify stock is taking a beating on Wednesday after shares of SHOP were hit with a downgrade from Wedbush analyst Scott Devitt. 
Via InvestorPlace
Why Is Pharvaris (PHVS) Stock Up 36% Today?
Pharvaris stock is rising higher on Wednesday following news of an underwritten offering for PHVS shares and pre-funded warrants. 
Via InvestorPlace
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 27% Today?
ZyVersa Therapeutics stock is rising with heavy trading of ZVSA shares after a paper was published in a peer-reviewed journal. 
Via InvestorPlace
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.